Sacroiliac Joint Fusion Injections Rf Ablation Market Report: Market Size & Forecast 2026

The SI joint fusion, injections, and RF ablation market addresses a well-documented source of chronic axial low back pain, with treatment options spanning fluoroscopically guided intra-articular corticosteroid injections, cooled radiofrequency neurotomy of lateral branch nerves, and minimally invasive fusion using triangular titanium implants. The market is currently valued at roughly $0.85 billion in 2025 and is projected to grow at about 14.5% annually through the forecast horizon, outpacing many adjacent interventional spine segments. Demand is supported by epidemiologic trends in chronic low back pain and increasing procedural volumes documented in Medicare administrative datasets.

• •Procedural volumes for spinal fusion interventions, including SI joint procedures, are projected to continue rising through 2050 based on Medicare utilization data.
• •The SI joint is recognized as a primary pain generator in an estimated 15-30% of chronic low back pain cases, supporting a sizable addressable patient pool.
• •CMS national health expenditure projections through 2032 point to continued growth in overall medical and surgical spending, providing a supportive macroeconomic backdrop.

Market expansion is being driven by stronger clinical evidence validating cooled RF ablation and minimally invasive SI joint fusion versus non-surgical management, alongside updated evidence-based guidelines from professional societies. Demographic aging, rising rates of degenerative spine disease, and improved payer coverage for image-guided interventional procedures are also contributing to volume growth. In addition, the integration of artificial intelligence into interventional spine workflows is expected to enhance patient selection and procedural precision.

• •Level-1 evidence and 12-month outcome data demonstrate sustained pain relief and functional gains from cooled RF ablation and triangular titanium rod fusion.
• •Practice guidelines from ASPN formalize indications for SI joint injections and ablation, supporting broader clinician adoption.
• •An aging global population is increasing the prevalence of degenerative sacroiliac pathology and associated chronic pain.

The market is commonly segmented by procedure type, including diagnostic and therapeutic SI joint injections, radiofrequency ablation (conventional and cooled), and minimally invasive SI joint fusion with implants. North America leads in procedural volume and revenue, supported by established reimbursement pathways, high specialist density, and robust clinical trial activity, while Europe represents the second-largest region with growing guideline-driven uptake. The Asia-Pacific region is expected to register the fastest growth, driven by expanding interventional pain training programs, rising healthcare expenditure, and improved access to fluoroscopy and imaging infrastructure.

• •Cooled RF ablation is gaining share over conventional RF due to larger lesion size and longer duration of pain relief.
• •Minimally invasive fusion with triangular titanium implants is the fastest-growing procedural subsegment based on Level-1 comparative evidence.
• •Asia-Pacific is forecast to expand at the highest regional CAGR as healthcare systems scale interventional pain services.

What are the recent trends and outlook?

Emerging trends include wider adoption of cooled RF ablation protocols, expanded use of minimally invasive triangular titanium implant fusion, and the integration of AI-enabled planning and intraoperative guidance tools into interventional spine practice. Guideline updates from bodies such as the American Society of Pain and Neuroscience are expected to further standardize indications and reinforce payer coverage. Over the forecast period, the combination of demographic aging, stronger clinical evidence, and technology adoption supports a continued double-digit growth trajectory for the SI joint fusion, injections, and RF ablation market.

• •AI-assisted patient selection and imaging guidance are moving from guideline discussion to early clinical implementation.
• •Evidence supporting cooled RF ablation over standard medical management is reshaping treatment algorithms for chronic SI joint pain.
• •Continued procedure volume growth and reimbursement stability are expected to sustain a CAGR of approximately 14.5% through the forecast horizon.